A simple, repeatable way to completely remove a clot from the brain in one pass

2026-07-22

Stroke is the third most common cause of death globally and is the leading cause of adult physical disability. Globally, seventeen million people had a stroke in 20152. Of these, 33% died and 33% were permanently disabled. A stroke occurs when a blood vessel in the brain is blocked by a clot, preventing blood flow, and causing brain damage. Stroke is a devastating disease. Perfuze has developed aspiration catheter technology intended to ingest the clot in a single attempt. No accessory devices or sophisticated techniques are required, meaning the procedure can be performed by a single operator. This maximises the chance of complete clot ingestion within the occluded vessel, complete flow restoration and improved patient outcomes. Multiple iterations have been required to reach the existing Millipede design. Pilot manufacturing lines utilising customised coiling and wire forming equipment have been built. Component and assembly drawings and specifications have been defined. Six preclinical animal studies have been performed to compliment proof-of-concept bench testing. The potential market opportunity is huge. In the US and EU alone, it is valued at $2.5bn in 2018. The Perfuze platform is uniquely positioned to exploit the recent, dramatic clinical shift away from medical therapy to endovascular device treatment of ischemic stroke. This SME Instrument Phase 2 will enable company scale up and creation of 52 jobs by 2024 and will generate over €17m in turnover.

Ireland

2026-02-15